Shanghai Shen Lian Biomedical Corp Cash Flow Conversion Efficiency
Shanghai Shen Lian Biomedical Corp cash flow conversion efficiency. Based on the latest financial reports, Shanghai Shen Lian Biomedical Corp (688098) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥21.52 Million ≈ $3.15 Million USD) by net assets (CN¥1.42 Billion ≈ $207.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shanghai Shen Lian Biomedical Corp (2013–2025)
Cash flow conversion efficiency of Shanghai Shen Lian Biomedical Corp from 2013 to 2025. This chart illustrates how Shanghai Shen Lian Biomedical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 688098 live share price for real-time trading data and today's change.
Shanghai Shen Lian Biomedical Corp Cash Flow Conversion Ratio Explained
Shanghai Shen Lian Biomedical Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shanghai Shen Lian Biomedical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Shen Lian Biomedical Corp ranked by their cash flow conversion efficiency. Also see Shanghai Shen Lian Biomedical Corp (688098) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allied Circuit Co Ltd
TWO:8155
|
0.060x |
|
Ningbo Zhongbai Co Ltd
SHG:600857
|
0.015x |
|
Bannari Amman Sugars Limited
NSE:BANARISUG
|
0.130x |
|
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
IS:GENIL
|
0.018x |
|
Tianshui Zhongxing Bio-technology Co Ltd
SHE:002772
|
0.058x |
|
Anhui Wantong Technology Co Ltd
SHE:002331
|
-0.065x |
|
Petpal Pet Nutrition Technology Co Ltd
SHE:300673
|
0.013x |
|
Zhengzhou J and T Hi Tech Co
SHE:300845
|
0.021x |
Annual Cash Flow Conversion Efficiency for Shanghai Shen Lian Biomedical Corp (2013–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Shen Lian Biomedical Corp from 2013 to 2025. Review Shanghai Shen Lian Biomedical Corp (688098) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.40 Billion ≈ $204.71 Million |
CN¥33.08 Million ≈ $4.84 Million |
0.024x | -62.28% |
| 2024-12-31 | CN¥1.43 Billion ≈ $208.61 Million |
CN¥89.36 Million ≈ $13.08 Million |
0.063x | +2579.52% |
| 2023-12-31 | CN¥1.51 Billion ≈ $220.53 Million |
CN¥3.53 Million ≈ $515.90K |
0.002x | -61.47% |
| 2022-12-31 | CN¥1.50 Billion ≈ $219.04 Million |
CN¥9.09 Million ≈ $1.33 Million |
0.006x | -90.08% |
| 2021-12-31 | CN¥1.47 Billion ≈ $215.54 Million |
CN¥90.12 Million ≈ $13.19 Million |
0.061x | -23.54% |
| 2020-12-31 | CN¥1.40 Billion ≈ $204.32 Million |
CN¥111.73 Million ≈ $16.35 Million |
0.080x | +90.53% |
| 2019-12-31 | CN¥1.28 Billion ≈ $187.49 Million |
CN¥53.81 Million ≈ $7.87 Million |
0.042x | -71.15% |
| 2018-12-31 | CN¥831.94 Million ≈ $121.74 Million |
CN¥121.13 Million ≈ $17.73 Million |
0.146x | +7.20% |
| 2017-12-31 | CN¥549.27 Million ≈ $80.38 Million |
CN¥74.61 Million ≈ $10.92 Million |
0.136x | +31.73% |
| 2016-12-31 | CN¥465.47 Million ≈ $68.11 Million |
CN¥48.00 Million ≈ $7.02 Million |
0.103x | +6.05% |
| 2015-12-31 | CN¥317.41 Million ≈ $46.45 Million |
CN¥30.86 Million ≈ $4.52 Million |
0.097x | -77.84% |
| 2014-12-31 | CN¥241.57 Million ≈ $35.35 Million |
CN¥105.98 Million ≈ $15.51 Million |
0.439x | +177.50% |
| 2013-12-31 | CN¥327.59 Million ≈ $47.94 Million |
CN¥51.79 Million ≈ $7.58 Million |
0.158x | -- |
About Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.